<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773876</url>
  </required_header>
  <id_info>
    <org_study_id>1126</org_study_id>
    <secondary_id>2011-005451-14</secondary_id>
    <nct_id>NCT01773876</nct_id>
  </id_info>
  <brief_title>Empirical Antifungal Treatment in ICUS</brief_title>
  <acronym>EMPIRICUS</acronym>
  <official_title>Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive Candida infections are burdened with a high mortality rate and is very common in
      intensive care units. This study aims to evaluate the efficacy of empirical treatment with
      micafungin in adult patients with suspected invasive candidiasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, randomized, double-blind parallel groups comparing adult patients with suspected
      invasive candidiasis input from a 14-day empirical treatment with micafungin (MYCAMINE 100
      mg) with placebo on survival without invasive candidiasis in 28 days after initiation of
      study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival to 28 days without proven fungal infection (a fungal infection occurring within 48 hours after inclusion will be considered available for inclusion)</measure>
    <time_frame>28 days follow-up</time_frame>
    <description>breakthrough infection defined as a proven infection occurs at least 48 hours after initiation of treatment Proven infection is considered purchased after enrollment if the first significant positive levy occurs after the 48 th hour after enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameters: estimated gross exposure indices: AUC, Cmax, Cmin</measure>
    <time_frame>during 24 hours (between the two first infusions)</time_frame>
    <description>Reports AUC / MIC and Cmax / MIC will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of tolerance</measure>
    <time_frame>3 months</time_frame>
    <description>For all patients who received at least one dose of treatment:
number of adverse events reported after randomization up to 28 days, only death will count up to 3 months post-randomization (information on the long-term survival collected by telephone),
changes in the clinical examination, vital signs and laboratory results,
overall survival defined as the time from randomization to date of death from any cause.
Changes in liver function tests (bilirubin, ALT, AST, rate prothrombin, alkaline phosphatase) at the end of treatment and at the end study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic parameters: potential serum biomarkers of treatment efficacy (PCR Candida,1,3 β-D-glucan,mannan antigenemia,anti-mannan,Procalcitonin (proCT))</measure>
    <time_frame>during 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacodynamic parameters: Early prognostic factors of response: J7 survival without proven invasive candidiasis</measure>
    <time_frame>during 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible on all-cause mortality at day 28 (end of study) and J90 (3 months post-randomization)</measure>
    <time_frame>during 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis can free survival antifungal treatment at day 28</measure>
    <time_frame>during 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible evolution of organ failure during the study</measure>
    <time_frame>during 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible the use of mechanical ventilation during the study</measure>
    <time_frame>during 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible evolution of the colonization index during study</measure>
    <time_frame>during 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible changes in serum biomarkers (1-3 β-D-glucan, mannan antigenemia, anti-mannan Candida PCR) during the study</measure>
    <time_frame>during 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of empiric treatment with micafungin in patients with invasive candidiasis possible on the incidence of pneumonia acquired bacterial mechanical ventilation (VAP).</measure>
    <time_frame>during 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Invasive Candidiasis</condition>
  <arm_group>
    <arm_group_label>Micafungin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MYCAMINE 100 mg intravenous an injection of 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chlorides 100ml infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin</intervention_name>
    <description>MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%
infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis</description>
    <arm_group_label>Micafungin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Persistent sepsis without documented invasive candidiasis:

        systemic inflammatory response syndrome (SIRS) presence of two signs on the 4 [temperature
        &lt;36 ° C or&gt; 38 ° C, heart rate&gt; 90/min, respiratory rate&gt; 20/min or PaCO2 &lt;32 mmHg,
        leukocytosis&gt; 12,000 / mm3, &lt;4.000/mm3 or presence of circulating immature forms (&gt; 10% of
        cells)] mechanical ventilation (intubation or tracheostomy) for over 4 days (96 hours)
        central line use of broad-spectrum antibacterial for more than 4 calendar days (96 hours)
        in the previous week presence of at least one extra-digestive site colonized by Candida sp.
        (Urine, mouth, throat, upper and lower respiratory tract, skin folds, and suction drains
        after surgery ...), not lower digestive tract, are not taken into account the positive
        samples of rectal swabs and / or stool cultures, absence of proven bacterial infections
        untreated no evidence of invasive fungal infections (positive blood culture, positive
        culture of a surgical site, deep biopsy with fungal) infection or mold according to the
        criteria of the group &quot;fungal infection of the EORTC&quot; organ failure

          -  Hospitalization in intensive care for over 5 days (120 hours)

          -  Giving a free, informed and in writing. In the absence of the person of trust or a
             family member (if present)consent to emergency possible.

          -  Receiving a social security system,

          -  Negative pregnancy test for patients of childbearing age

        Exclusion Criteria:

          -  Proven invasive fungal infection (positive blood culture, positive culture of a
             surgical site, deep biopsy with fungal infection), including aspergillosis requiring
             antifungal therapy at the time of randomization

          -  Prognosis of less than 48 hours (for which the patient outcome will be fatal whatever
             treatment),

          -  Echinocandin antifungal treatment by more than one day or another antifungal for over
             72 hours in the week before the inclusion visit,

          -  Allergy, hypersensitivity or known intolerance to echinocandins antifungal or any of
             the excipients of the drug

          -  Neutropenia (ANC &lt;500/mm3)

          -  History of organ and bone marrow,

          -  Recent chemotherapy (less than 6 months)

          -  Systemic immunosuppressive therapy in progress, other than with corticosteroids at
             doses below 2 mg / kg / day of prednisolone or equivalent

          -  Participation in another interventional study in the same ICU stay or making treatment
             being evaluated within 28 days prior to randomization

          -  Any clinical investigator deems incompatible with the conduct of the study in
             acceptable security conditions

          -  Pregnant and lactating women,

          -  Adults subject to a legal protection measure

          -  Persons deprived of their liberty by a judicial or administrative decision, those
             hospitalized without consent, persons admitted to a health facility or social purposes
             other than research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TIMSIT JFT Jean François, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Aix en Provence</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University of Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Avicennes</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University of Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Draguignan</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>96433</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interegional Hospital André Grégoire</name>
      <address>
        <city>Montreuil</city>
        <zip>93105</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of La Pitié Salpetrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital St Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University of Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Pontoise</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University of Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Departemental Hospital of Roche sur Yon</name>
      <address>
        <city>Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>survival without proven invasive candidiasis</keyword>
  <keyword>effectiveness</keyword>
  <keyword>micafungin versus placebo</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

